PURPOSE: To define and incorporate the impact of the @entity12740 ( @entity12740 ) into a predictive model of @entity263 radiotherapy biochemical outcome. METHODS AND MATERIALS: The data of 3264 @entity1 with clinically localized @entity263 treated with external beam radiotherapy at four institutions were retrospectively analyzed. Standard prognostic and treatment factors plus the number of biopsy cores collected and the number positive for @entity5 by transrectal ultrasound-guided biopsy were available. The primary endpoint was biochemical failure (bF, Phoenix definition). Multivariate proportional hazards analyses were performed and expressed as a nomogram and the model's predictive ability assessed using the concordance index (c-index). RESULTS: The cohort consisted of 21% low-, 51% intermediate-, and 28% high-risk @entity5 @entity1 , and 30% had @entity342 deprivation with radiotherapy. The median @entity12740 was 50% (interquartile range [IQR] 29-67%), and median follow-up was 51 months (IQR 29-71 months). Percentage of positive biopsy cores displayed an independent association with the risk of bF (p=0.01), as did age, @entity1486 value, Gleason score, clinical stage, @entity342 deprivation duration, and radiotherapy dose (p<0.001 for all). Including @entity12740 increased the c-index from 0.72 to 0.73 in the overall model. The influence of @entity12740 varied significantly with radiotherapy dose and clinical stage (p=0.02 for both interactions), with doses<66 Gy and palpable @entity5 showing the strongest relationship between @entity12740 and bF. Intermediate-risk @entity1 were poorly discriminated regardless of @entity12740 inclusion (c-index 0.65 for both models). CONCLUSIONS: Outcome models incorporating @entity12740 show only minor additional ability to predict biochemical failure beyond those containing standard prognostic factors.

Percentage of biopsy cores positive for XXXX and biochemical failure following @entity263 radiotherapy in 3,264 @entity1 : statistical significance without predictive performance.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignancy', 'tumors'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity12740 :: ('MESH:D020512', 'Disease') :: ['PPC', 'percentage of positive biopsy cores'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity5 :: (MESH:D009369,Disease) :: ['malignancy']
